Len A Pennacchio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6581847/publications.pdf

Version: 2024-02-01

154 papers 34,259 citations

82 h-index 157 g-index

177 all docs

177 docs citations

177 times ranked

41531 citing authors

#	Article	IF	Citations
1	Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nature Genetics, 2008, 40, 1461-1465.	21.4	2,764
2	A Common Allele on Chromosome 9 Associated with Coronary Heart Disease. Science, 2007, 316, 1488-1491.	12.6	1,591
3	ChIP-seq accurately predicts tissue-specific activity of enhancers. Nature, 2009, 457, 854-858.	27.8	1,526
4	The amphioxus genome and the evolution of the chordate karyotype. Nature, 2008, 453, 1064-1071.	27.8	1,496
5	Expanded encyclopaedias of DNA elements in the human and mouse genomes. Nature, 2020, 583, 699-710.	27.8	1,252
6	Metagenomic Discovery of Biomass-Degrading Genes and Genomes from Cow Rumen. Science, 2011, 331, 463-467.	12.6	1,135
7	In vivo enhancer analysis of human conserved non-coding sequences. Nature, 2006, 444, 499-502.	27.8	1,072
8	VISTA Enhancer Browsera database of tissue-specific human enhancers. Nucleic Acids Research, 2007, 35, D88-D92.	14.5	950
9	Dicer, Drosha, and Outcomes in Patients with Ovarian Cancer. New England Journal of Medicine, 2008, 359, 2641-2650.	27.0	633
10	Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nature Genetics, 2007, 39, 1007-1012.	21.4	624
11	Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 17921-17926.	7.1	606
12	Genomic views of distant-acting enhancers. Nature, 2009, 461, 199-205.	27.8	549
13	Most Rare Missense Alleles Are Deleterious in Humans: Implications for Complex Disease and Association Studies. American Journal of Human Genetics, 2007, 80, 727-739.	6.2	547
14	Gain-of-function SOS1 mutations cause a distinctive form of Noonan syndrome. Nature Genetics, 2007, 39, 75-79.	21.4	523
15	Enhancer redundancy provides phenotypic robustness in mammalian development. Nature, 2018, 554, 239-243.	27.8	514
16	Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nature Genetics, 2007, 39, 513-516.	21.4	473
17	Massively parallel functional dissection of mammalian enhancers in vivo. Nature Biotechnology, 2012, 30, 265-270.	17.5	468
18	The amphioxus genome illuminates vertebrate origins and cephalochordate biology. Genome Research, 2008, 18, 1100-1111.	5.5	456

#	Article	IF	Citations
19	Enhancers: five essential questions. Nature Reviews Genetics, 2013, 14, 288-295.	16.3	455
20	Targeted deletion of the 9p21 non-coding coronary artery disease risk interval in mice. Nature, 2010, 464, 409-412.	27.8	425
21	ChIP-Seq identification of weakly conserved heart enhancers. Nature Genetics, 2010, 42, 806-810.	21.4	395
22	Disruption of an AP-2α binding site in an IRF6 enhancer is associated with cleft lip. Nature Genetics, 2008, 40, 1341-1347.	21.4	382
23	Mutation of SHOC2 promotes aberrant protein N-myristoylation and causes Noonan-like syndrome with loose anagen hair. Nature Genetics, 2009, 41, 1022-1026.	21.4	358
24	Two independent apolipoprotein A5 haplotypes influence human plasma triglyceride levels. Human Molecular Genetics, 2002, 11, 3031-3038.	2.9	352
25	The Epigenomic Landscape of Prokaryotes. PLoS Genetics, 2016, 12, e1005854.	3.5	348
26	Rapid and Pervasive Changes in Genome-wide Enhancer Usage during Mammalian Development. Cell, 2013, 155, 1521-1531.	28.9	342
27	Genomic strategies to identify mammalian regulatory sequences. Nature Reviews Genetics, 2001, 2, 100-109.	16.3	341
28	Relative contribution of variation within the APOC3/A4/A5 gene cluster in determining plasma triglycerides. Human Molecular Genetics, 2002, 11, 3039-3046.	2.9	335
29	Progressive ataxia, myoclonic epilepsy and cerebellar apoptosis in cystatin B-deficient mice. Nature Genetics, 1998, 20, 251-258.	21.4	332
30	Human-Specific Gain of Function in a Developmental Enhancer. Science, 2008, 321, 1346-1350.	12.6	330
31	Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. Journal of Clinical Investigation, 2009, 119, 70-9.	8.2	322
32	Genetic dissection of the α-globin super-enhancer in vivo. Nature Genetics, 2016, 48, 895-903.	21.4	308
33	Genomic Patterns of De Novo Mutation in Simplex Autism. Cell, 2017, 171, 710-722.e12.	28.9	308
34	Combinatorial Regulation of Endothelial Gene Expression by Ets and Forkhead Transcription Factors. Cell, 2008, 135, 1053-1064.	28.9	306
35	Ultraconservation identifies a small subset of extremely constrained developmental enhancers. Nature Genetics, 2008, 40, 158-160.	21.4	299
36	The DNA sequence and biology of human chromosome 19. Nature, 2004, 428, 529-535.	27.8	298

#	Article	IF	Citations
37	Single-nucleus analysis of accessible chromatin in developing mouse forebrain reveals cell-type-specific transcriptional regulation. Nature Neuroscience, 2018, 21, 432-439.	14.8	290
38	Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 16224-16229.	7.1	285
39	Cathepsin L is required for endothelial progenitor cell–induced neovascularization. Nature Medicine, 2005, 11, 206-213.	30.7	278
40	Progressive Loss of Function in a Limb Enhancer during Snake Evolution. Cell, 2016, 167, 633-642.e11.	28.9	275
41	A restricted spectrum of NRAS mutations causes Noonan syndrome. Nature Genetics, 2010, 42, 27-29.	21.4	271
42	Principles of regulatory information conservation between mouse and human. Nature, 2014, 515, 371-375.	27.8	259
43	Large-scale discovery of enhancers from human heart tissue. Nature Genetics, 2012, 44, 89-93.	21.4	257
44	An atlas of dynamic chromatin landscapes in mouse fetal development. Nature, 2020, 583, 744-751.	27.8	257
45	Deletion of Ultraconserved Elements Yields Viable Mice. PLoS Biology, 2007, 5, e234.	5.6	255
46	Apolipoprotein AV Accelerates Plasma Hydrolysis of Triglyceriderich Lipoproteins by Interaction with Proteoglycan-bound Lipoprotein Lipase. Journal of Biological Chemistry, 2005, 280, 21553-21560.	3.4	253
47	A High-Resolution Enhancer Atlas of the Developing Telencephalon. Cell, 2013, 152, 895-908.	28.9	241
48	Germline Chd8 haploinsufficiency alters brain development in mouse. Nature Neuroscience, 2017, 20, 1062-1073.	14.8	210
49	Fine Tuning of Craniofacial Morphology by Distant-Acting Enhancers. Science, 2013, 342, 1241006.	12.6	209
50	Unstable minisatellite expansion causing recessively inherited myoclonus epilepsy, EPM1. Nature Genetics, 1997, 15, 393-396.	21.4	207
51	Homotypic clusters of transcription factor binding sites are a key component of human promoters and enhancers. Genome Research, 2010, 20, 565-577.	5.5	203
52	Medical Sequencing at the Extremes of Human Body Mass. American Journal of Human Genetics, 2007, 80, 779-791.	6.2	199
53	Apolipoprotein A5, a Crucial Determinant of Plasma Triglyceride Levels, Is Highly Responsive to Peroxisome Proliferator-activated Receptor \hat{l}_{\pm} Activators. Journal of Biological Chemistry, 2003, 278, 17982-17985.	3.4	186
54	Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5. Biochemical and Biophysical Research Communications, 2004, 319, 397-404.	2.1	183

#	Article	IF	Citations
55	Genome resequencing reveals multiscale geographic structure and extensive linkage disequilibrium in the forest tree <i>Populus trichocarpa</i> . New Phytologist, 2012, 196, 713-725.	7.3	173
56	Ultraconserved Enhancers Are Required for Normal Development. Cell, 2018, 172, 491-499.e15.	28.9	169
57	Close sequence comparisons are sufficient to identify human cis-regulatory elements. Genome Research, 2006, 16, 855-863.	5.5	164
58	The sequence and analysis of duplication-rich human chromosome 16. Nature, 2004, 432, 988-994.	27.8	156
59	<i>Apolipoprotein A5</i> , a Newly Identified Gene That Affects Plasma Triglyceride Levels in Humans and Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 529-534.	2.4	150
60	Apoa5 Q139X truncation predisposes to late-onset hyperchylomicronemia due to lipoprotein lipase impairment. Journal of Clinical Investigation, 2005, 115, 2862-2869.	8.2	147
61	Dynamic GATA4 enhancers shape the chromatin landscape central to heart development and disease. Nature Communications, 2014, 5, 4907.	12.8	142
62	Dlx1&2-Dependent Expression of Zfhx1b (Sip1, Zeb2) Regulates the Fate Switch between Cortical and Striatal Interneurons. Neuron, 2013, 77, 83-98.	8.1	140
63	Directed Evolution of Ionizing Radiation Resistance in <i>Escherichia coli</i> Bacteriology, 2009, 191, 5240-5252.	2.2	131
64	The changing mouse embryo transcriptome at whole tissue and single-cell resolution. Nature, 2020, 583, 760-767.	27.8	131
65	Apolipoprotein A-V Deficiency Results in Marked Hypertriglyceridemia Attributable to Decreased Lipolysis of Triglyceride-Rich Lipoproteins and Removal of Their Remnants. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2573-2579.	2.4	125
66	Functional importance of cardiac enhancer-associated noncoding RNAs in heart development and disease. Journal of Molecular and Cellular Cardiology, 2014, 76, 55-70.	1.9	124
67	Predicting tissue-specific enhancers in the human genome. Genome Research, 2007, 17, 201-211.	5.5	117
68	A large genomic deletion leads to enhancer adoption by the lamin B1 gene: a second path to autosomal dominant adult-onset demyelinating leukodystrophy (ADLD). Human Molecular Genetics, 2015, 24, 3143-3154.	2.9	117
69	A Cryptochrome 2 mutation yields advanced sleep phase in humans. ELife, 2016, 5, .	6.0	114
70	52 Genetic Loci Influencing MyocardialÂMass. Journal of the American College of Cardiology, 2016, 68, 1435-1448.	2.8	113
71	Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Human Molecular Genetics, 2009, 18, 1140-1147.	2.9	112
72	Enhancer Variants Synergistically Drive Dysfunction of a Gene Regulatory Network In Hirschsprung Disease. Cell, 2016, 167, 355-368.e10.	28.9	112

#	Article	IF	CITATIONS
73	Comparative genomic analysis as a tool for biological discovery. Journal of Physiology, 2004, 554, 31-39.	2.9	105
74	Tissue-Specific RNA Expression Marks Distant-Acting Developmental Enhancers. PLoS Genetics, 2014, 10, e1004610.	3.5	105
75	Cathepsin B but not cathepsins L or S contributes to the pathogenesis of Unverricht-Lundborg progressive myoclonus epilepsy (EPM1). Journal of Neurobiology, 2003, 56, 315-327.	3.6	102
76	The DNA sequence and comparative analysis of human chromosome 5. Nature, 2004, 431, 268-274.	27.8	102
77	Occupancy by key transcription factors is a more accurate predictor of enhancer activity than histone modifications or chromatin accessibility. Epigenetics and Chromatin, 2015, 8, 16.	3.9	100
78	Comprehensive InÂVivo Interrogation Reveals Phenotypic Impact of Human Enhancer Variants. Cell, 2020, 180, 1262-1271.e15.	28.9	100
79	Transcriptional Regulation of Enhancers Active in Protodomains of the Developing Cerebral Cortex. Neuron, 2014, 82, 989-1003.	8.1	99
80	Lack of MEF2A mutations in coronary artery disease. Journal of Clinical Investigation, 2005, 115, 1016-1020.	8.2	99
81	Linkage and Association Between Distinct Variants of the APOA1/C3/A4/A5Gene Cluster and Familial Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 167-174.	2.4	97
82	Enhancer identification through comparative genomics. Seminars in Cell and Developmental Biology, 2007, 18, 140-152.	5.0	97
83	Haplotype analysis of the apolipoprotein gene cluster on human chromosome 11. Genomics, 2004, 83, 912-923.	2.9	95
84	Array comparative genomic hybridization in patients with congenital diaphragmatic hernia: mapping of four CDH-critical regions and sequencing of candidate genes at 15q26.1–15q26.2. European Journal of Human Genetics, 2006, 14, 999-1008.	2.8	91
85	Insulin-Mediated Down-Regulation of Apolipoprotein A5 Gene Expression through the Phosphatidylinositol 3-Kinase Pathway: Role of Upstream Stimulatory Factor. Molecular and Cellular Biology, 2005, 25, 1537-1548.	2.3	88
86	Spatiotemporal DNA methylome dynamics of the developing mouse fetus. Nature, 2020, 583, 752-759.	27.8	84
87	Genome-wide compendium and functional assessment of in vivo heart enhancers. Nature Communications, 2016, 7, 12923.	12.8	83
88	Brg1 modulates enhancer activation in mesoderm lineage commitment. Development (Cambridge), 2015, 142, 1418-30.	2.5	81
89	Gain-of-Function R225W Mutation in Human AMPKÎ ³ 3 Causing Increased Glycogen and Decreased Triglyceride in Skeletal Muscle. PLoS ONE, 2007, 2, e903.	2.5	80
90	Evolution of extreme resistance to ionizing radiation via genetic adaptation of DNA repair. ELife, 2014, 3, e01322.	6.0	80

#	Article	IF	CITATIONS
91	Association of common variants in the Joubert syndrome gene (AHI1) with autism. Human Molecular Genetics, 2008, 17, 3887-3896.	2.9	79
92	Improved regulatory element prediction based on tissue-specific local epigenomic signatures. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, E1633-E1640.	7.1	78
93	In vivo characterization of a vertebrate ultraconserved enhancer. Genomics, 2005, 85, 774-781.	2.9	77
94	The Liver X Receptor Ligand T0901317 Down-regulates APOA5 Gene Expression through Activation of SREBP-1c. Journal of Biological Chemistry, 2004, 279, 45462-45469.	3.4	76
95	Analysis of Apolipoprotein A5, C3, and Plasma Triglyceride Concentrations in Genetically Engineered Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1297-1302.	2.4	76
96	Neuropathological Changes in a Mouse Model of Progressive Myoclonus Epilepsy: Cystatin B Deficiency and Unverricht-Lundborg Disease. Journal of Neuropathology and Experimental Neurology, 2002, 61, 1085-1091.	1.7	72
97	Apolipoprotein AIV Gene Variant S347 Is Associated With Increased Risk of Coronary Heart Disease and Lower Plasma Apolipoprotein AIV Levels. Circulation Research, 2003, 92, 969-975.	4.5	71
98	Function-based identification of mammalian enhancers using site-specific integration. Nature Methods, 2014, 11, 566-571.	19.0	71
99	Supervised enhancer prediction with epigenetic pattern recognition and targeted validation. Nature Methods, 2020, 17, 807-814.	19.0	71
100	Identification of Novel Craniofacial Regulatory Domains Located far Upstream of <i>SOX9 </i> Disrupted in Pierre Robin Sequence. Human Mutation, 2014, 35, 1011-1020.	2.5	69
101	Insights from human/mouse genome comparisons. Mammalian Genome, 2003, 14, 429-436.	2.2	68
102	Genomic Resolution of DLX-Orchestrated Transcriptional Circuits Driving Development of Forebrain GABAergic Neurons. Cell Reports, 2019, 28, 2048-2063.e8.	6.4	68
103	Activating Mutations Affecting the Dbl Homology Domain of SOS2 Cause Noonan Syndrome. Human Mutation, 2015, 36, 1080-1087.	2.5	67
104	Tissue-specific SMARCA4 binding at active and repressed regulatory elements during embryogenesis. Genome Research, 2014, 24, 920-929.	5.5	63
105	Comparative genomic tools and databases: providing insights into the human genome. Journal of Clinical Investigation, 2003, 111, 1099-1106.	8.2	60
106	Massively parallel sequencing identifies the gene <i>Megf8</i> with ENU-induced mutation causing heterotaxy. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 3219-3224.	7.1	57
107	Functional autonomy of distant-acting human enhancers. Genomics, 2009, 93, 509-513.	2.9	56
108	An etiologic regulatory mutation in IRF6 with loss- and gain-of-function effects. Human Molecular Genetics, 2014, 23, 2711-2720.	2.9	55

#	Article	IF	CITATIONS
109	Relationship between genetic variation at PPP1R3B and levels of liver glycogen and triglyceride. Hepatology, 2018, 67, 2182-2195.	7.3	51
110	Transcriptional Regulation of Apolipoprotein A5 Gene Expression by the Nuclear Receptor ROR $\hat{l}\pm$. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 1186-1192.	2.4	50
111	TIMELESS mutation alters phase responsiveness and causes advanced sleep phase. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 12045-12053.	7.1	50
112	Human cathepsin L rescues the neurodegeneration and lethality in cathepsin B/L double-deficient mice. Biological Chemistry, 2006, 387, 885-891.	2.5	49
113	Lack of Support for the Association between GAD2 Polymorphisms and Severe Human Obesity. PLoS Biology, 2005, 3, e315.	5.6	44
114	Presynaptic Homeostasis Opposes Disease Progression in Mouse Models of ALS-Like Degeneration: Evidence for Homeostatic Neuroprotection. Neuron, 2020, 107, 95-111.e6.	8.1	43
115	Dynamic BAF chromatin remodeling complex subunit inclusion promotes temporally distinct gene expression programs in cardiogenesis. Development (Cambridge), 2019, 146, .	2.5	39
116	Ultraconserved enhancer function does not require perfect sequence conservation. Nature Genetics, 2021, 53, 521-528.	21.4	39
117	Genetic and functional analyses identify <i>DISC1</i> as a novel callosal agenesis candidate gene. American Journal of Medical Genetics, Part A, 2011, 155, 1865-1876.	1.2	38
118	ATAC-Seq Reveals an <i>Isl1</i> Enhancer That Regulates Sinoatrial Node Development and Function. Circulation Research, 2020, 127, 1502-1518.	4.5	35
119	Congenital Heart Defects in Patients with Deletions Upstream of <i>SOX9 </i> . Human Mutation, 2013, 34, 1628-1631.	2.5	33
120	Brg1 coordinates multiple processes during retinogenesis and is a tumor suppressor in retinoblastoma. Development (Cambridge), 2015, 142, 4092-4106.	2.5	30
121	Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons. American Journal of Human Genetics, 2018, 103, 874-892.	6.2	30
122	A Genetic Signature of Spina Bifida Risk from Pathway-Informed Comprehensive Gene-Variant Analysis. PLoS ONE, 2011, 6, e28408.	2.5	29
123	A PYY Q62P variant linked to human obesity. Human Molecular Genetics, 2006, 15, 387-391.	2.9	28
124	Use of "MGE Enhancers―for Labeling and Selection of Embryonic Stem Cell-Derived Medial Ganglionic Eminence (MGE) Progenitors and Neurons. PLoS ONE, 2013, 8, e61956.	2.5	28
125	Identification of a novel enhancer of brain expression near the apoE gene cluster by comparative genomics. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2004, 1676, 41-50.	2.4	26
126	Generation of Long Insert Pairs Using a Cre-LoxP Inverse PCR Approach. PLoS ONE, 2012, 7, e29437.	2.5	26

#	Article	IF	CITATIONS
127	Haplotypes in the APOA1-C3-A4-A5 gene cluster affect plasma lipids in both humans and baboons. Human Molecular Genetics, 2004, 13, 1049-1056.	2.9	25
128	In vivo characterization of human APOA5 haplotypes. Genomics, 2007, 90, 674-679.	2.9	25
129	Transcriptional network orchestrating regional patterning of cortical progenitors. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118 , .	7.1	25
130	Noncoding deletions reveal a gene that is critical for intestinal function. Nature, 2019, 571, 107-111.	27.8	24
131	Long-read metagenomics of soil communities reveals phylum-specific secondary metabolite dynamics. Communications Biology, 2021, 4, 1302.	4.4	21
132	Comparative genomic tools and databases: providing insights into the human genome. Journal of Clinical Investigation, 2003, 111, 1099-1106.	8.2	20
133	Characterization of Mammalian In Vivo Enhancers Using Mouse Transgenesis and CRISPR Genome Editing. Methods in Molecular Biology, 2022, 2403, 147-186.	0.9	20
134	Reactivation of a developmentally silenced embryonic globin gene. Nature Communications, 2021, 12, 4439.	12.8	19
135	Characterization of the human neurocan gene, CSPG3. Gene, 1998, 221, 199-205.	2.2	18
136	The INSIG2 rs7566605 genetic variant does not play a major role in obesity in a sample of 24,722 individuals from four cohorts. BMC Medical Genetics, 2009, 10, 56.	2.1	17
137	Limb-Enhancer Genie: An accessible resource of accurate enhancer predictions in the developing limb. PLoS Computational Biology, 2017, 13, e1005720.	3.2	17
138	Comparative genomic analysis reveals a distant liver enhancer upstream of the COUP-TFII gene. Mammalian Genome, 2005, 16, 91-95.	2.2	16
139	Glucose Regulates the Expression of the Apolipoprotein A5 Gene. Journal of Molecular Biology, 2008, 380, 789-798.	4.2	16
140	Differences in enhancer activity in mouse and zebrafish reporter assays are often associated with changes in gene expression. BMC Genomics, 2012, 13, 713.	2.8	16
141	Coding and noncoding variants in EBF3 are involved in HADDS and simplex autism. Human Genomics, 2021, 15, 44.	2.9	16
142	Perfect and imperfect views of ultraconserved sequences. Nature Reviews Genetics, 2022, 23, 182-194.	16.3	16
143	Limits of sequence and functional conservation. Nature Genetics, 2010, 42, 557-558.	21.4	15
144	Deletion of a non-canonical regulatory sequence causes loss of Scn1a expression and epileptic phenotypes in mice. Genome Medicine, 2021, 13, 69.	8.2	15

#	Article	IF	CITATIONS
145	Single site-specific integration targeting coupled with embryonic stem cell differentiation provides a high-throughput alternative to in vivo enhancer analyses. Biology Open, 2013, 2, 1229-1238.	1.2	11
146	Stable enhancers are active in development, and fragile enhancers are associated with evolutionary adaptation. Genome Biology, 2019, 20, 140.	8.8	11
147	Structure, sequence and location of the UQCRFS1 gene for the human Rieske Fe-S protein. Gene, 1995, 155, 207-211.	2.2	10
148	Differential Etv2 threshold requirement for endothelial and erythropoietic development. Cell Reports, 2022, 39, 110881.	6.4	9
149	HAND transcription factors cooperatively specify the aorta and pulmonary trunk. Developmental Biology, 2021, 476, 1-10.	2.0	7
150	Contrasting Patterns of Sequence Evolution at the Functionally Redundant bric à brac Paralogs in Drosophila melanogaster. Journal of Molecular Evolution, 2009, 69, 194-202.	1.8	5
151	Comparative Genomics. Methods in Molecular Biology, 2007, 366, 229-251.	0.9	4
152	Comparative and functional analysis of cardiovascular-related genes. Pharmacogenomics, 2003, 4, 571-582.	1.3	1
153	Genomic Resolution of DLX-Orchestrated Transcriptional Circuits Driving Development of Forebrain GABAergic Neurons. SSRN Electronic Journal, 0, , .	0.4	0
154	Comparative Genomics: A Tool to Functionally Annotate Human DNA., 0,, 229-252.		0